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Objective: The purpose of the trial was to examine the effects of amantadine, 
a N-methyl-D-aspartate (NMDA) antagonist, on the oral glucose tolerance test (OGTT) plus 
insulin, glucagon and neurotransmitters circulating levels. Previous findings showed that 
hyperinsulinism and type 2 diabetes are positively associated with neural sympathetic and 
adrenal sympathetic activities, respectively. These peripheral sympathetic branches depend 
on the pontine (A5-noradrenergic) and the rostral ventrolateral (C1-adrenergic) medullary 
nuclei. They are excited by glutamate axons which act at NMDA postsynaptic receptors.
Research design and methods: One OGTT plus placebo and one OGTT plus oral amantadine 
test were carried out two weeks apart in 15 caucasic normal voluntary humans. Noradrenaline, 
adrenaline, dopamine, plasma-free serotonin, platelet serotonin, glucose, glucagon, and insulin 
were measured throughout the 180-minute testing period.
Results: Maximal reductions of plasma glucose and glucagon plus exacerbated insulin rises 
were significantly greater throughout the oral glucose plus amantadine test than those registered 
throughout the oral glucose plus placebo challenge. The above findings were paralleled by greater 
than normal noradrenaline/adrenaline plasma ratio increases. In addition, maximal reductions of 
the platelet serotonin and plasma serotonin circulating values contrasted with the normal rises 
of these parameters, always registered during the glucose load plus placebo challenge.
Conclusion: This study supports the theory that amantadine might be a powerful antidiabetic 
tool and could be added to the therapeutic arsenal against type 2 diabetes.
Keywords: glucagon, insulin, type 2 diabetes, sympathetic nervous system, blood serotonin, 
blood catecholamines, amantadine
Introduction
The interaction between alpha- and beta-islet cells is responsible for plasma 
glucose homeostasis.1 Predominance of the former and the latter are responsible 
for hyperglycemia2–4 and hypoglycemia,4,5 respectively. In addition, this binomial 
peripheral crosstalk is modulated by several physiological factors which include both 
peripheral neuroendocrine and central nervous system (CNS) mechanisms.6,7 However, 
this physiological stability can be disrupted by many stressor factors such as exercise 
and restraint,8,9 neuropharmacological agents such as tianeptine (enhancer of serotonin 
uptake),10 doxepin (inhibitor of serotonin uptake),11 or dopaminergic-blocking agents 
(such as sulpiride, haloperidol).12,13 Quantitative and/or qualitative changes of the above 
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with this issue has investiged the peripheral mechanisms 
involved in the alpha-cell versus beta-cell crosstalk 
(endocrine, gastrointestinal, and neuroautonomic); however, 
little research work has been devoted to the understanding of 
the CNS circuitry responsible for the alpha- versus beta-cells 
interaction and/or CNS versus peripheral autonomic nervous 
system (ANS) parameters. The investigation of such crosstalk 
might redound in findings able to lead to the outlining of 
adequate neuropharmacological therapeutical strategies 
addressed to normalize the peripheral disorders responsible 
for the alpha-cells ↔ beta-cells imbalance.
Evidence have demonstrated that insulin excites 
neural sympathetic activity14,15 while glucagon excites 
adrenal sympathetic activity.16–18 In addition, both 
sympathetic branches of the peripheral ANS depend on 
the A5 pontomedullary nucleus that releases noradrena-
line (NA)19 and the C1 medullary nuclei which secrete 
adrenaline (Ad).20–24 Furthermore, both CNS nuclei inter-
change direct inhibitory axons whose neurotransmitters 
act at post-synaptic alpha-2 receptors, which crowd both 
nuclei.18–25 Finally, experimental evidence has demonstrated 
that secretion of both peripheral hormones (insulin and 
glucagon) would depend on the interaction between 
two opposite neuroendocrine circuits. According to the 
above, we decided to investigate the effect of amantadine, 
a glutamic acid (N-methyl-D-aspartate [NMDA]) antagonist, 
which inhibits the C1 (Ad) but not the A5 (NA) nuclei, and 
provokes absolute reduction of plasma adrenaline concentra-
tion when administered to normal subjects during fasting 
conditions.26–31
Methods
One oral glucose tolerance test (OGTT) plus placebo 
and one OGTT plus oral amantadine (100 mg) test were 
carried out two weeks apart in 15 caucasic normal volun-
tary humans (seven males and eight females), whose ages 
ranged from 25 to 58 years (mean ± standard error of mean 
[SEM] = 38.4 ± 7.2) (Tables 1–3). The study was conducted 
in accordance with the guidelines in the Declaration of 
Helsinki. Written informed consent was obtained after the 
purpose, nature and potential risks had been explained to 
the subjects. The experimental protocol was approved by 
the Ethical Committee of FUNDAIME. All subjects were 
within 10% of ideal body weight, and none had undergone 
abdominal surgery or were taking any medications. None of 
the subjects had physical or psychiatric illness. Subjects were 
rated on a modified Hamilton Depression Rating Scale for 
depression and all of them completed the self-rating Beck 
Depression Inventory11 in order to discard subjects with 
depression. Pregnancy, lactation, smoking and/or alcoholism 
factors also excluded subjects.
Analytical methods
The assessment of circulating neurotransmitters throughout 
the OGTT + placebo test carried out according to the 
present protocol ratified other previously published research 
studies.10,11 Noradrenaline, adrenaline, dopamine, plasma 
free serotonin (f5-HT), platelet serotonin (p5-HT), glucose, 
glucagon, and insulin were measured throughout the 
180-minute testing period. For all parameters, the samples 
were assayed in duplicate and all determinations were 
made simultaneously. We used reverse-phase, ion-pair high 
performance liquid chromatography with electrochemical 
detection for the detection of monoamines. Optimization 
of chromatographic conditions and attainment of adequate 
quantification parameters allowed us to maximize sensitivity 
and reproducibility.
All tests were performed on recumbent subjects after 
14 hours of fasting. A heparinized venous catheter was 
inserted into a forearm vein at least 30 minutes before begin-
ning the tests. Blood samples were collected at 0, 30, 60, 90, 
120, and 180 minutes. Each subject drank a 30% glucose 
solution (1 g/kg of ideal body weight) plus placebo or an 
oral dose of amantadine (100 mg = one capsule). Blood 
for catecholamines and serotonin assays was transferred to 
plastic tubes, each containing 20 mg of EDTA plus 10 mg 
of sodium bisulphite/ml of solution. The tubes were care-
fully inverted and placed on ice. The blood was promptly 
centrifuged at 600 rpm for 15 minutes at 4°C in order to 
obtain platelet-rich plasma. Two milliliters of platelet-rich 
plasma, obtained for determination of platelet serotonin 
(p5-HT), were taken and stored at –70°C until assayed. The 
remaining blood was again centrifuged at 7,000 rpm. The 
supernatant, platelet-poor plasma, was divided into four 
portions for determination of insulin, glucagon, catechol-
amines and free serotonin (f5-HT), after which all portions 
were stored at -70°C until assayed. Plasma glucose samples 
were immediately processed.
Reagents and standards
Noradrenaline, adrenaline, dopamine, serotonin creatinine 
sulphate, dihydroxybenzylamine, sodium octyl sulphate, 
dibutylamine, acid-washed aluminium oxide, Na2HPO4, 
citric acid and EDTA were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Microfilters were purchased from 
Whatman Inc. (Florham Park, NY, USA) through Merck Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 205
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S.A. (Caracas, Venezuela). Acetonitrile and 2-propanol 
were obtained from Merck, S.A. Glass-distilled water was 
de-ionized and filtered through a Milli-Q reagent grade 
water system (Millipore, Bedford, MA, USA). Solvents 
were filtered through a 0.2 µm Millipore filter and were 
vacuum de-aerated. Standard solutions (1 mmo1/L) were 
prepared in 0.1 mo1/L perchloric acid and diluted to the 
desired concentration.
equipment
Liquid chromatography was performed using Waters 
515 HPLC pump (Waters Corporation, Milford, MA. USA) 
equipped with a Rheodyne valve injector 7125i, which 
was fitted with a 50 µL sample loop (Rheodyne; Berodine, 
Berkeley, CA, USA). A 15 cm × 4.6 mm inner diameter 
Discovery C18 column packed with octadecylsilane 5 µm 
particles was preceded by a column prefilter of 2 µm poros-
ity, both from Supelco/Sigma-Aldrich. The detection sys-
tem was a Waters 460 Electrochemical Detector (Waters 
Corporation). The potential of the working electrode (glass 
carbon) was set at + 0.61 V versus the Ag–AgCl reference 
electrode for the detection of catecholamines and 0.70 V 
versus the Ag–AgCl for the detection of indolamines. The 
chromatograms were registered and quantified with Empower 
software (Waters Corporation). The results were corrected 
for the volume of EDTA added.
Analytical assays
Plasma catecholamines
The assay was performed by extraction of the catechol-
amines onto 20 mg of alumina followed by their elution with 
200 µL of 1.0 mo1/L HClO4 using regenerated cellulose 
Table 1 correlations found during the oral glucose tolerance + placebo test performed in 15 normal voluntary human (seven males 
and eight females)
Periods
  0 min 30 min 60 min 90 min 120 min 180 min
nA vs Ad ns ns ns ns ns ns
nA vs DA ns ns 0.203* 0.256* 0.321** 0.293**
Ad vs DA ns ns ns ns ns ns
nA vs glycemia ns ns -0.221* -0.325** -0.442** -0.456**
DA vs glycemia ns ns -0.211* -0.247* -0.354** -0.376**
Ad vs glycemia ns ns ns ns ns ns
nA vs p5-hT ns ns ns ns ns ns
Ad vs p5-hT ns ns ns ns ns ns
DA vs p5-hT ns ns ns ns ns ns
p5-hT vs glycemia ns ns ns ns ns ns
nA vs insulin ns ns 0.325* 0.411** 0.401** 0.397**
DA vs insulin ns ns 0.214* 0.222* 0.216* 0.217*
Ad vs insulin ns ns ns ns ns ns
p5-hT vs insulin ns ns -0.212* -0.223 -0.231* -0.214*
nA vs glucagon ns ns -0.299* -0.297* -0.365** -0.377**
DA vs glucagon ns ns ns -0.288* -0.322* -0.315*
Ad vs glucagon ns ns ns ns ns ns
P5-hT vs glucagon ns ns ns ns ns ns
nA vs hR ns ns ns ns ns ns
Ad vs hR ns ns ns ns ns ns
DA vs hR ns ns ns ns ns ns
nA/Ad vs SBP ns ns ns ns ns ns
nA/Ad vs DBP ns ns 0.207* 0.214* 0.221* 0.218*
DA vs SBP ns ns ns ns ns ns
DA vs DBP ns ns -0.213* -0.210* -0.220* -0.222*
Notes: Levels of significance, *P  0.05; **P  0.01.
Abbreviations: nA, noradrenaline;      Ad, adrenaline; DA, dopamine; p5-hT, platelet serotonin; f5-hT, plasma serotonin; hR, heart rate; SBP, systolic blood pressure; DBP, diastolic 
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microfilters 0.2 µm pore size (Whatman Inc.). We calibrated 
the instrument with standard plasma. After incubation 
with acid-washed aluminum oxide, a plasma pool of free 
catecholamines was processed similarly to plasma samples, 
but 20 µL of a standard solution of noradrenaline, adrena-
line, and dopamine (50, 25, and 25 ng/mL, respectively) 
were added to the plasma pool. Both the standard plasma 
and the sample plasma were supplemented with 20 µL of 
internal standard (100 ng/mL of dihydroxybenzylamine). 
The mobile phase was KH2PO4 6.8045 g/L, EDTA 0.100 g/L 
and di-N-butylamine 100 µl/L. Sodium octyl sulphate was 
added as ion-pair agent in a concentration of 0.6125 g/L with 
the pH adjusted to 5.6. The flow rate was 0.400 mL/min. 
The sensitivity of this method for noradrenaline, adrenaline 
and dopamine was 6.4, 5.8, and 2.0 pg/mL, respectively. 
The intraassay coefficients of variation were 2.8%, 4.0%, and 
4.0 %, respectively. The inter-assay coefficients of variation 
were 6.7%, 4.5%, and 4.3%, respectively.
Plasma indolamines
After sonication of platelet-rich plasma to disrupt the 
platelets (Ultrasonic Liquid Processor, model 385; Heat 
Systems Ultrasonics Inc., Farmingdale, NY, USA), both 
platelet-rich and platelet-poor plasma were processed in the 
same way: 200 µL of 3.4 mol/L perchloric acid and 50 µl of 
5-hydroxy-tryptophan solution (114.5 µg/mL) as internal stan-
dard, were added to 1 mL of plasma vortexed and centrifuged 
at 10,000 rpm for 15 minutes at 4°C. The supernatant 
was filtered through a 0.22 µm membrane (Millipore) and 
10 µL was injected into the column. Calibration runs were 
Table 2 correlations found during the oral glucose tolerance + amantadine test performed in 15 normal voluntary human (seven males 
and eight females)
Periods
  0 min 30 min 60 min 90 min 120 min 180 min
nA vs Ad ns ns ns ns ns ns
nA vs DA ns ns 0.368** 0.377** 0.405** 0.426**
Ad vs DA ns ns ns ns ns ns
nA vs glycemia ns ns -0.267* -0.338** -0.422** -0.439**
DA vs glycemia ns ns -0.332* -0.365* -0.411** -0.395**
Ad vs glycemia ns ns ns ns ns ns
nA vs p5-hT ns ns -0.244* -0.332* -0.326* -0.299*
Ad vs p5-hT ns ns ns ns ns ns
DA vs p5-hT ns ns -0.237* -0.314* -0.333* ns
p5-hT vs glycemia ns ns 0.244* 0.338* 0.352* 0.341*
nA vs insulin ns ns 0.211* 0.253* 0.324** 0.323**
DA vs insulin ns ns 0.199* 0.218* 0.235* 0.239*
Ad vs insulin ns ns ns ns ns ns
p5-hT vs insulin ns ns -0.368** -0.387** -0.359** -0.371**
nA vs glucagon ns ns -0.318* -0.409** -0.396** -0.402**
DA vs glucagon ns ns -0.297* -0.346* -0.401** -0.411**
Ad vs glucagon ns ns ns ns ns ns
P5-hT vs glucagon ns ns ns 0.363* 0.402** 0.416**
nA vs hR ns ns ns ns ns ns
Ad vs hR ns ns ns ns ns ns
DA vs hR ns ns ns ns ns ns
nA/Ad vs SBP ns ns ns ns ns ns
nA/Ad vs DBP ns ns 0.232* 0.229* 0.239* 0.241*
DA vs SBP ns ns ns ns ns ns
DA vs DBP ns ns -0.218* -0.222* -0.219* -0.231*
Notes: Levels of significance, *P  0.05; **P  0.01.
Abbreviations: nA, noradrenaline;    Ad, adrenaline; DA, dopamine; p5-hT, platelet serotonin; f5-hT, plasma serotonin; hR, heart rate; SBP, systolic blood pressure; DBP, 
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generated by spiking blank platelet-poor plasma with 50 µL 
of a solution containing 5-HT (10 µg/mL) and 50 µL of 
5-hydroxy-tryptophan (114.5 µg/mL). This standard plasma 
was processed in the same manner as the samples. The mobile 
phase was citric acid 3.8424 g/L, sodium acetate 4.1015 g/L, 
EDTA 0.100 g/L, di-N-butylamine 100 µl/L, and 30 ml/L of 
2-propanol. Sodium octyl sulphate was added as ion-pair agent 
in a concentration of 4.25 mg/L with a pH of 5.0. The flow rate 
was 0.610 mL/min. The sensitivity of the method for serotonin 
was 0.1 ng/mL. The intra-assay coefficients of variation for 
p5-HT and f5-HT were 6.2% and 8.7%, respectively.
Plasma insulin
This was determined in duplicate by insulin ELISA kit 
(Cosmo Bio, Carlsbad, CA, USA).
Plasma glucagon
Plasma glucagon was determined by radioimmunoassay 
(RIA) kit GL-32K (Linco Research; Millipore). In our hands, 
the intraassay variation was 4.5 ± 1.2 and 11.1 ± 2.8 for the 
interassay variation.
Plasma glucose
Plasma glucose concentration was measured in duplicate 
with a glucose oxidase method32 using Glucose Analyzer II 
(Beckman Instruments, Fullerton, CA, USA).
Statistical methods
Results are presented as the mean ± SEM. Statistical 
significance was set at *P  0.05; **P  0.02; ***P  0.01 
(versus 0 min value). Multivariate ANOVA with repeated 
measurements, paired t test, and correlation coeffi-
cients (exploratory factor analysis) were used. dBase 
Stats™ (Ashton Tate, Chicago, IL, USA) and StatView 
SE + Graphics (SAS Institute, Cary, NC, USA) were used 
for statistical analyses.
Results
Oral glucose + placebo test
Suppression of plasma glucagon concentration was observed 
throughout the test with a nadir of 40.0 ± 5.0 pg/mL at the 
90-minute period. Maximal rise of glucose was registered 
at the 30-minute period, whereas minimal mean values were 
reached at the 180-minute period (Figure 1). Noradrena-
line and platelet serotonin circulating parameters showed 
significant and sustained rises which paralleled insulin 
increases and opposed plasma glucose reductions. Significant 
reduction of adrenaline values were registered throughout the 
test. Dopamine did not show significant changes (Figure 2). 
In addition to the above, although both noradrenaline and 
platelet serotonin concentrations were raised after the oral 
glucose load, the noradrenaline/p5-HT ratio showed signifi-
cant falls throughout the OGTT (Figure 3). No significant 
f5-HT changes were registered throughout the test. All 
of our subjects fell asleep and displayed rapid eye move-
ments (REM) during OGTT, especially accentuated at the 
90-minute and 180-minute periods.
Oral glucose + amantadine test
Subjects showed drowsiness but not REM sleep throughout 
the test. Adrenaline showed maximal and sustained decreases 
throughout the post-amantadine periods. Conversely, 
significant and sustained noradrenaline plus dopamine rises 
opposed the adrenaline falls. In addition, abrupt fall of 
f5-HT and p5-HT parameters were also registered throughout 
the OGTT + amantadine challenge (Figure 4).
Maximal and sustained reductions of  both plasma glucose 
and glucagon were observed. Small and sustained but 
significant insulin rises were registered throughout post-
glucose + amantadine periods (Figure 1). Maximal fall of 
systolic blood pressure and heart rate, were also observed 
throughout the post-drug + glucose periods.
Discussion
The results obtained from the present study demonstrated 
that the addition of a small dose of amantadine (100 mg) 
to the OGTT was able to enhance the insulinogenic plus 
hypoglycemic effects normally triggered by the ingested 
sugar. These effects were paralleled by the enhancement of 
the normal neural sympathetic overactivity, always registered 
throughout the OGTT as well as by the accentuation of 
Table 3 changes in SBP, DBP, and hR induced in 15 normal 
voluntary healthy humans (eight males and seven females) when 
one OgTT plus placebo and one OgTT plus amantadine tests 
were carried out two weeks apart
OGTT + placebo  
test
OGTT + amantadine   
test
  0 min 180 min 0 min 180 min
hR (beats/min) 71 ± 5 66 ± 7* 73 ± 7 65 ± 8**
SBP (mm hg) 127 ± 8 122 ± 3 127 ± 8 124 ± 7
DBP (mm hg) 73 ± 5 76 ± 4* 71 ± 6 88 ± 4**
Notes: Results are expressed as mean ± SeM. *P  0.05; **P  0.01 (versus 
0 min value).
Abbreviations: DBP, diastolic blood pressure; hR, heart rate; OgTT, oral glucose 
tolerance test; SBP, systolic blood pressure; SeM, standard error of mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 208
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Figure 1 The addition of an oral dose of amantadine (100 mg) to an oral glucose load potentiated both the glucose and glucagon reductions and increased postprandial insulin 
levels in 15 normal healthy subjects (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SeM = 38.4 ± 7.2).
Notes:  Values are expressed as mean ± SeM *P  0.05; **P  0.02 (versus 0 min value).
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Figure 2 The addition of an oral dose of amantadine (100 mg) to an oral glucose load enhanced the normal noradrenaline and dopamine rises, always observed throughout 
the OgTT + placebo test. conversely, maximal reduction of adrenaline opposed the former rises. 
Notes: n = 15 (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SeM = 38.4 ± 7.2).    Values are expressed as mean ± SeM. *P  0.05; **P  0.02; 
***P  0.01 (versus 0 min value).
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the fall of the adrenaline plus glucagon plasma levels 
that occurs after an oral glucose load. Both insulin and 
glucagon cross the blood–brain barrier and excite the A5 
(NA)14,17,33,34 and the C1 (Ad)16,33–36 pontomedullary nuclei, 
respectively. The former is responsible for the peripheral 
neural (noradrenergic) sympathetic activity whereas the lat-
ter excites adrenal sympathetic glands, which secrete 80% of 
adrenaline. The fact that glutamatergic axons innervate and 
excite the C1 (Ad) but not the A5 (NA) neurons (by acting 
at NMDA receptors) explains why amantadine (a NMDA 
antagonist) interferes with the adrenal but not with the neural 
sympathetic activity. With respect to this, experimental 
evidences obtained from our laboratory, demonstrated that 
a small dose of amantadine (administered without glucose) 
provokes absolute minimization of the adrenaline plasma 
concentration.24,29
In addition to all the above, some other factors should 
be considered in order to understand the ability by amanta-
dine to annul the glucagon-induced excitatory effect at the 
CNS C1 (Ad) + peripheral adrenal sympathetic axis, which 
would explain its insulinogenic + hypoglycemic effects. For 
instance, the drug was able to provoke maximal reduction of 
both plasma serotonin and platelet serotonin concentration. 
This circulating indolamine exerts an inhibitory effect at the 
beta-cell level and in addition is able to excite alpha-cells, 
which secrete glucagon.37–41 Furthermore, plasma serotonin 
is able to excite the adrenal glands,39,42 directly. Thus, the 
reduction of plasma serotonin plus platelet serotonin circu-
lating values registered in the present study should be taken 
into account in order to understand the hypoglycemic effect 
triggered by amantadine, when this drug was added to an 
oral glucose load.
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Figure 3 The insulin/glucagon ratio as well as the noradrenaline/adrenaline ratio showed paralleled increases throughout the oral glucose tolerance test when 100 mg of oral 
amantadine was given to 15 normal healthy subjects (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SeM = 38.4 ± 7.2).
Notes:  Values are expressed as mean ± SeM. *P  0.05; **P  0.02 (versus 0 min value).
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The minimization of  the circulating serotonin concentration 
(plasma serotonin + platelet serotonin) registered in the 
present study might find an explanation in the overwhelm-
ing neural sympathetic over adrenal sympathetic activity 
triggered by amantadine. It should be remembered that the 
release of serotonin from the enterochromaffin cells depends 
on the excitatory parasympathetic drive which should be 
interfered by the enhancement of the neural sympathetic 
activity (noradrenaline/adrenaline ratio) registered in this 
study.40,43–48 The minimization of the plasma acetylcho-
line concentration, which competes with serotonin for 
the platelet uptake, fits well with the maximal reduction 
of the plasma serotonin values registered during the post 
amantadine periods. This postulation is in accordance 
with the maximal fall of systolic blood pressure and heart 
rate, observed throughout the post-drug periods. Both 
cardiovascular parameters are positively correlated with the 
peripheral adrenal sympathetic activity greatly minimized 
in the present study because of the inhibition by amantadine 
of the C1 (Ad) medullary nuclei.
In addition to the above, it has been shown that other 
drugs like tianeptine, which also minimizes plasma serotonin 
concentration is able to enhance plasma insulin secretion.10 
This fact should be attributed to the direct inhibitory 
effect exerted by this indolamine at the beta-cell level.
The enhancement of the noradrenaline/adrenaline 
plasma ratio registered in the present study indicates 
that the overwhelming neural sympathetic activity 
annulled the peripheral adrenal sympathetic branch. This 
peripheral neuroautonomic profile depends on the absolute 
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Figure 4 Both platelet serotonin (p5-hT) and plasma serotonin (f5-hT) showed maximal decreases throughout the test when an oral dose of amantadine (100 mg) was added 
to an oral glucose load.    These findings contrast with the significant rises of both parameters observed throughout the oral glucose load + placebo challenge.
Notes: n = 15 (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SeM = 38.4 ± 7.2).    Values are expressed as mean ± SeM. *P  0.05; ***P  0.01 
(versus 0 min value).
Abbreviation: SeM, standard error of mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 212
Lechin et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
predominance of the A5 (NA) pontomedullary nucleus 
over the C1 (Ad) medullary nuclei.24,49 The above CNS A5 
(NA) versus C1 (Ad) predominance which redounded in 
the peripheral neural sympathetic plus beta-cells hyperac-
tivity merits some additional comments. With respect to 
this, it should be known that sympathetic nerves innervate 
and excite alpha-cells by acting at alpha-2 receptors but 
not beta-cells.20–22,50 However, glucagon released from the 
former excites beta-cells which send GABA-inhibitory 
drive to alpha-cells.41 In addition to the above, it should be 
remembered that both adrenaline and glucagon are positively 
correlated with glucogenolysis and hyperglycemia both of 
which are absolutely minimized in the present research 
study.
According to all the above, we postulate that the post-
prandial hypoglycemic + insulinogenic effects provoked 
by the addition of a small dose of amantadine to the OGTT 
depends on peripheral + central nervous system mecha-
nisms. The former should be attributed to the minimization 
of the inhibitory effect of circulating serotonin (plasma 
serotonin + platelet serotonin) plus the suppression of the 
glucogenolytic effect by adrenaline. At the central nervous 
system the above phenomena would depend on the inhi-
bition of the C1 (Ad) medullary nuclei plus the absolute 
predominance of the A5 (NA) nucleus. Both insulin and 
glucagon cross the blood brain barrier and excite the A5 
(NA) and the C1 (Ad) pontomedullary nuclei, respectively 
thus, the inhibition of the latter triggered by amantadine 
provoked the abrupt suppression of the adrenal glands 
secretion which favored the absolute predominance of 
the A5 (NA) neural sympathetic branch that resulted in 
the enhancement of insulin/glucagon ratio, registered in 
this study. This postulation receives definite support from 
overwhelming evidence quoted in several review articles 
and books.24,29,41,51,52
Summarizing all the above, it is possible to postulate 
that the hypoglycemic + hypoglucagonemic + insulinogenic 
effects triggered by the addition of amantadine to an 
oral glucose load would depend of both peripheral plus 
central nervous system mechanisms. The former should be 
associated to the minimization of the alpha-cells + adrenal 
glands secretion whereas the latter should be associated with 
the inhibition of the C1 (Ad) plus the disinhibition of the A5 
(NA), responsible for the peripheral adrenal sympathetic 
and neural sympathetic branches axis, respectively.
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